Sector: MedicalSavient Pharmaceuticals Inc (NASDAQ: SVNT)
Headlines
- Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
Nov 04, 2009 07:24 PM | SVNT
- Savient Pharmaceuticals to Hold Third Quarter 2009 Financial Results Conference Call on Thursday, November 5, 2009
Oct 28, 2009 06:33 PM | SVNT
- Savient Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference
Oct 27, 2009 04:32 PM | SVNT
- Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
Oct 15, 2009 11:22 AM | SVNT
- Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
Oct 08, 2009 07:54 PM | SVNT
- Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
Oct 07, 2009 04:01 PM | SVNT
- Savient Pharmaceuticals to Present At JMP Securities 4th Annual Healthcare Focus Conference
Oct 01, 2009 12:11 PM | SVNT
- Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
Sep 16, 2009 06:00 AM | SVNT
- Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting
Sep 08, 2009 08:01 AM | SVNT
- Indices Rally, But Give Back A Big Chunk Of Post-FOMC Gains
Aug 12, 2009 11:50 PM | BCRX, BEXP, GS, HGSI, MOS, OREX
- Savient Pharmaceuticals Secures $60 Million in Public Offering
Oct 16, 2009 09:53 AM | SVNT
- BofA, Ford, Alcoa, Huron Consulting are big movers
Aug 03, 2009 07:13 PM | AA, BAC, BCS, C, F, HURN
- FedEx, Beazer Homes, Netflix are big movers
Jun 17, 2009 05:51 PM | BBI, BZH, ETFC, FDX, NFLX, RAI
- BenchmarkJournal.Com Free Analyst Review for VPRT, ARCC, STAR, VRNM, XOMA and SVNT
Aug 26, 2009 07:11 AM | ARCC, STAR, SVNT, VPRT, VRNM, XOMA
- Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results ; Ends First Half of 2009 With $76.6M in Cash and Short-Term Investments
Aug 10, 2009 02:55 PM | SVNT
- Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results
Aug 10, 2009 06:52 AM | SVNT
- Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
Aug 02, 2009 06:01 PM | SVNT
- Lawrence Gyenes Appointed Chief Financial Officer of Columbia Laboratories
Jul 15, 2009 09:55 AM | CBRX, SVNT, ZILA
- FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
Jun 16, 2009 04:00 PM | SVNT
- Savient Announces Election of Dr. Ginger D. Constantine to Board of Directors
Jun 05, 2009 07:01 AM | SVNT
- Savient to Present Multiple Abstracts At the European League Against Rheumatism (EULAR) 2009 Annual Congress
May 29, 2009 09:19 AM | SVNT
- Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
May 07, 2009 12:47 PM | SVNT
- Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
May 06, 2009 07:56 PM | SVNT
- Form 4 Gionco David For: Feb 27 (10K)
Sep 15, 2009 07:15 PM
- Form 4 Hamelin Paul For: Sep 11 (10K)
Sep 15, 2009 07:11 PM
- Form 4 YACHMETZ PHILIP K For: Sep 14 (10K)
Sep 15, 2009 07:11 PM
- Form 3 Constantine Ginger For: Jun 05 (10K)
Jun 11, 2009 04:32 PM
- Form 4 SAVIENT PHARMACEUTICALS For: May 26 Filed by: Hamelin Paul (10K)
May 26, 2009 06:57 PM
- Form 4 JAEGER STEPHEN O For: May 05 (10K)
May 14, 2009 05:18 PM
- Form 4 THOMPSON VIRGIL For: May 05 (10K)
May 13, 2009 05:44 PM
- Form 4 HELLER ALAN L For: May 05 (10K)
May 13, 2009 02:02 PM
- Form 4 KLEIN JOSEPH III For: May 05 (10K)
May 13, 2009 01:59 PM
- Form 4 Simon Lee S For: May 05 (10K)
May 13, 2009 01:59 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
SVNT
|
Compare to S&P
|
| YTD |
138.51 %
|
97.40 %
|
| 4 Weeks |
-0.50 %
|
-1.58 %
|
| 12 Weeks |
0.66 %
|
-5.10 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -31.25 %
|
|
EPS Growth in Last Year: -31.25 %
|
|
Sales Growth in Last Quarter: -51.76 %
|
|
Sales Growth in Last Quarter: -39.48 %
|
|
